Computed Tomography Devices Market Forecast 2032: FDA Clears 4DMedical's CT:VQ Trademark , the First-and-Only CT-Based VQ Imaging Solution | DelveInsight

The CT scanners market is set to grow steadily, driven by rising demand for advanced imaging, technological innovations, and expanding use in cardiology, oncology, and respiratory care. Increasing chronic disease prevalence and focus on early, accurate diagnosis are boosting adoption of CT scan devices and types of CT scanners in hospitals and imaging centers.
In September 2025, 4DMedical received FDA 510(k) clearance for CT:VQ, the first non-contrast ventilation-perfusion (V/Q) imaging solution built on standard CT scan devices. Simultaneously, CMS confirmed Category III CPT reimbursement for CT:VQ, supplementing existing chest CT payments, bringing both clinical innovation and financial support for this breakthrough in respiratory imaging technology. DelveInsight's Computed Tomography (CT) Devices Market Insights report [https://www.delveinsight.com/report-store/computed-tomography-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=jpr] highlights how such FDA-cleared innovations, alongside advances in next-generation CT scanners, are reshaping the market outlook through 2032.

The market outlook remains strong as companies continue to innovate across different types of CT scanners, including high-slice, portable, and AI-enabled systems, aimed at improving speed, precision, and patient comfort. With FDA-cleared breakthroughs like CT:VQ and ongoing investments in advanced imaging, the CT devices market is expected to maintain steady momentum, offering transformative diagnostic capabilities and reshaping future standards of care.

Key Takeaways from the Computed Tomography Devices Market Report

- In September 2025, 4DMedical received FDA 510(k) clearance for CT:VQ, the first non-contrast ventilation-perfusion (V/Q) imaging solution built on standard CT scan devices. Simultaneously, CMS confirmed Category III CPT reimbursement for CT:VQ, supplementing existing chest CT payments-bringing both clinical innovation and financial support for this breakthrough in respiratory imaging technology.

- In May 2025, GE HealthCare (Nasdaq: GEHC) launched CleaRecon DL, an AI-powered deep-learning technology that enhances cone-beam CT (CBCT) image quality. Designed for use in liver, prostate, neuro, and endovascular aortic repair procedures, it reduces streak artifacts from blood flow and contrast changes. CleaRecon DL has received U.S. FDA 510(k) clearance and CE mark, and will be available on the Allia Trademark platform.

- In May 2025, GE HealthCare announced that the FDA granted 510(k) clearance for its Aurora nuclear medicine system and Clarify DL. This advanced dual-head SPECT/CT system is designed to enhance diagnostic capabilities and improve workflow efficiency, providing clinicians with superior image quality and streamlined operations.

- In April 2025, Brainomix announced FDA clearance of a novel feature in its Brainomix 360 Stroke solution that allows physicians to assess ischemic core volume using standard non-contrast CT (NCCT) images. This feature, validated by leading US stroke centers, shows accuracy comparable to CT Perfusion and MRI assessments.

- In March 2025, the FDA granted 510(k) clearance for Johnson & Johnson (J&J) MedTech's Monarch Quest for robotic-assisted bronchoscopy procedures. This solution features AI-powered algorithms and a verified OEC Open interface with GE HealthCare's OEC 3D mobile cone-beam CT imaging system, marking a new advancement in Monarch navigation technology.

- The global computed tomography (CT) devices market was valued at USD 8.4 billion in 2024 and is set to grow at a CAGR of 6.15%, reaching nearly USD 13.4 billion by 2032. Growth is driven by rising adoption of advanced CT scan devices and innovations across different types of CT scanners that enable faster, safer, and more precise imaging.

- Notable Computed Tomography Devices companies such as General Electric Company, FUJIFILM Holdings Corporation, Siemens Healthcare GmbH, Koninklijke Philips N.V., Canon Medical Systems Corporation, NeuroLogica Corp. (Samsung Electronics), Shimadzu Corp., Thermo Fisher Scientific, Xoran Technologies LLC, Trivitron Healthcare, Neusoft Medical Systems Co., Ltd., Shenzhen Anke High-Tech Co. Ltd., Shenzhen Basda Medical Apparatus Co. Ltd., PerkinElmer Inc., ICRco, Inc., MARS Bioimaging Ltd., United Imaging Healthcare Co., Ltd., SternMed GmbH, MinFound Medical Systems Co., Ltd., MR Solutions, and several others are currently operating in the Computed Tomography Devices market.

- As per DelveInsight estimates, North America is anticipated to dominate the global Computed Tomography Devices market during the forecast period.

To read more about the latest highlights related to the computed tomography devices market, get a snapshot of the key highlights entailed in the Global Computed Tomography Devices Market Report [https://www.delveinsight.com/sample-request/computed-tomography-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=jpr]

Computed Tomography Devices Overview

Computed tomography devices, commonly known as CT scan devices, are advanced imaging systems that use X-rays and computer processing to generate detailed cross-sectional images of the body. Widely adopted across oncology, cardiology, neurology, and respiratory care, modern CT scanners offer faster scan times, reduced radiation exposure, and higher resolution, enabling earlier and more accurate diagnosis. With continuous innovation across different types of CT scanners, from high-slice to portable and AI-enabled models, these systems are becoming central to precision medicine and routine clinical workflows worldwide.

Computed Tomography Devices Market Insights

North America is projected to dominate the global computed tomography (CT) devices market in 2024, supported by the high burden of cancer, respiratory, and cardiovascular diseases, alongside rapid technological advancements and frequent product approvals. According to GLOBOCAN (2024), cancer cases in the region are expected to rise from 2.67 million in 2022 to 3.83 million by 2045, making CT scan devices indispensable for tumor detection, progression monitoring, and treatment planning. Cardiovascular diseases also remain a major driver, with the CDC reporting millions of cases of coronary heart disease, atrial fibrillation, and stroke annually, further fueling demand for advanced CT scanners. Moreover, the U.S. continues to show high utilization of medical imaging among Medicare beneficiaries, underscoring reliance on diagnostic technologies. Product innovation, such as Siemens Healthineers' FDA-cleared photon-counting CT scanner Naeotom Alpha, highlights the region's leadership in cutting-edge types of CT scanners, positioning North America as a key growth engine for the CT devices market.

To know more about why North America is leading the market growth in the computed tomography devices market, get a snapshot of the Computed Tomography Devices Market Outlook [https://www.delveinsight.com/report-store/computed-tomography-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=jpr]

Computed Tomography Devices Market Dynamics

Rising disease prevalence continues to be the strongest driver of the global computed tomography (CT) devices market. In Australia alone, about 8.5 million people were living with chronic respiratory conditions in 2022, while worldwide, nearly 1 in 20 people are affected. Disorders such as COPD, pneumonia, and lung cancer require precise imaging, and advanced CT scan devices enable early detection, disease monitoring, and treatment planning. Cancer further fuels adoption, with GLOBOCAN estimating 20 million new cases in 2022 and projecting 32.6 million by 2045. CT scans remain central in tumor detection, staging, and CT-guided interventions.

Cardiovascular diseases add another primary growth driver, with 620 million people affected globally, where CT scanners play a critical role in angiography and heart disease management. Alongside disease burden, product innovation, such as Philips' Spectral CT 7500, continues to advance image quality, reduce rescans, and improve patient outcomes. While challenges like radiation exposure and regulatory hurdles persist, the increasing demand for early and accurate diagnosis across multiple disease areas ensures strong momentum for the CT devices market.

Get a sneak peek at the computed tomography devices market dynamics @ https://www.delveinsight.com/sample-request/computed-tomography-market [https://www.delveinsight.com/sample-request/computed-tomography-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=jpr]

Coverage: Global

Study Period: 2022 to 2032

Computed Tomography Devices Market CAGR: ~6.15%

Key Computed Tomography Devices Companies: General Electric Company, FUJIFILM Holdings Corporation, Siemens Healthcare GmbH, Koninklijke Philips N.V., Canon Medical Systems Corporation, NeuroLogica Corp. (Samsung Electronics), Shimadzu Corp., Thermo Fisher Scientific, Xoran Technologies LLC, Trivitron Healthcare, Neusoft Medical Systems Co., Ltd., Shenzhen Anke High-Tech Co. Ltd., Shenzhen Basda Medical Apparatus Co. Ltd., PerkinElmer Inc., ICRco, Inc., MARS Bioimaging Ltd., United Imaging Healthcare Co., Ltd., SternMed GmbH, MinFound Medical Systems Co., Ltd., MR Solutions, and others.

Computed Tomography Devices Market Segmentation

Market Segmentation By Type: Stationary CT Scanners and Portable CT Scanners.

Market Segmentation By Modality: O-Arm and C-Arm.

Market Segmentation By Technology: Low End, Mid-End, and High End.

Market Segmentation By Application: Oncology, Cardiology, Neurology, and others.

Market Segmentation By End User: Hospitals, Diagnostic Imaging Centers, and others.

Market Segmentation By Geography: North America, Europe, Asia-Pacific, and Rest of the World.

Which MedTech key players in the Computed Tomography Devices market are set to emerge as the trendsetter, explore @ Computed Tomography Devices Companies [https://www.delveinsight.com/sample-request/computed-tomography-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=jpr]

Table of Contents

1. Electrophysiology Devices Market Report Introduction

2. Electrophysiology Devices Market Executive Summary

3. Competitive Landscape

4. Regulatory Analysis

5. Electrophysiology Devices Market Key Factors Analysis

6. Electrophysiology Devices Market Porter's Five Forces Analysis

7. Electrophysiology Devices Market Layout

8. Electrophysiology Devices Market Company and Product Profiles

9. KOL Views

10. Project Approach

11. About DelveInsight

12. Disclaimer & Contact Us

About DelveInsight

DelveInsight is a premier healthcare business consultant and market research firm, specializing in life sciences. We empower pharmaceutical companies with comprehensive end-to-end solutions designed to enhance performance and drive growth.

Our expert healthcare consulting services offer in-depth market analysis, helping businesses accelerate growth and navigate challenges with actionable, results-driven strategies.

Media Contact
Company Name: DelveInsight
Contact Person: Jatin Vimal
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=computed-tomography-devices-market-forecast-2032-fda-clears-4dmedicals-ctvq-the-firstandonly-ctbased-vq-imaging-solution-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.